Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | QPCT | Q16769 | 1/20 | 0.47 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2069309 | 0.82 | NPC1 (0.47) | NPC1RAB9ATDP1MEN1KMT2A | |
| SCHEMBL2069839 | 0.82 | NPC1 (0.47) | NPC1RAB9ATDP1MEN1KMT2A | |
| SCHEMBL2069511 | 0.80 | NPC1 (0.57) | NPC1RAB9ATDP1MEN1KMT2A | |
| SCHEMBL10108701 | 0.78 | NPC1 (0.55) | NPC1RAB9ATDP1MEN1KMT2A | |
| SCHEMBL2070814 | 0.76 | NPC1 (0.53) | NPC1RAB9ATDP1MEN1KMT2A | |
| SCHEMBL2069838 | 0.75 | NPC1 (0.52) | NPC1RAB9ATDP1MEN1KMT2A | |
| SCHEMBL2069975 | 0.75 | CYP2D6 (0.53) | NPC1RAB9ATDP1MEN1KMT2A | |
| SCHEMBL2069519 | 0.73 | NPC1 (0.50) | NPC1RAB9ATDP1MEN1KMT2A | |
| SCHEMBL13915553 | 0.72 | TDP1 (0.34) | NPC1RAB9ATDP1LMNA | |
| SCHEMBL14168537 | 0.72 | NPC1 (0.49) | NPC1RAB9ATDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1938273-B | Tetrahydrocarbazoles and derivatives | HOFFMAN-LA ROCHE LTD. (CH) | 2011-12-14 | — | — | CN | disclosed |
| US-7906546-B2 | Tetrahydrocarbazoles and derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20100216833-A1 | TETRAHYDROCARBAZOLES AND DERIVATIVES | DEHMLOW HENRIETTA | 2010-08-26 | — | — | US | disclosed |
| EP-1732892-B1 | TETRAHYDROCARBAZOLES AND DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-09-17 | — | — | EP | disclosed |
| CN-1938273-A | Tetrahydrocarbazoles and derivatives | HOFFMANN LA ROCHE (CH) | 2007-03-28 | — | — | CN | disclosed |
| EP-1732892-A1 | TETRAHYDROCARBAZOLES AND DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005092856-A1 | TETRAHYDROCARBAZOLES AND DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-06 | — | — | WO | disclosed |
| US-20050215577-A1 | Tetrahydrocarbazoles and derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216833-A1 | TETRAHYDROCARBAZOLES AND DERIVATIVES | NR1H3, NR1H2, NR1H4 | NPC1 92/4885RAB9A 3611/4885TDP1 3388/4885 |
| US-20050215577-A1 | Tetrahydrocarbazoles and derivatives | NR1H3, NR1H2, NR1H4 | NPC1 92/4885RAB9A 3611/4885TDP1 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.